Glenn Bubley
Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Glenn Bubley

Internal Medicine
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
On Staff At

Advanced in WT1-Related Wilms Tumor Syndromes
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Glenn Bubley is an Internal Medicine provider in Boston, Massachusetts. Dr. Bubley is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Orchiectomy.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Michigan State University College Of Human Medicine
Residency
Saint Francis Hospital and Medical Center
Specialties
Internal Medicine
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine
Fellowships
Beth Israel Deaconess Medical Center
Hospital Affiliations
Beth Israel Deaconess Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, Boston, MA 02215
Call: 617-667-2100
Other Locations
BIDMC Needham Cancer Center
148 Chestnut Street, Needham, MA 02492
Call: 781-453-7500

Additional Areas of Focus

Dr. Bubley has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Bladder Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Radiation, Drug
Study Drugs: Bicalutamide, GnRH agonist, Darolutamide
Study Phase: Phase 2
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy
Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drugs: Apalutamide, Leuprolide, Prednisone, Abiraterone acetate
Study Phase: Phase 2
A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Radium-223, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug, Radiation
Study Drug: Enzalutamide
Study Phase: Phase 2
Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing
Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate
A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate
Enrollment Status: Terminated
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

53 Total Publications

Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 25, 2025
View All 53 Publications
Similar Doctors
David F. Mcdermott
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David F. Mcdermott
Internal Medicine | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David F. Mcdermott
Internal Medicine | Oncology

Beth Israel Deaconess Medical Center - Hematology/Oncology

330 Brookline Avenue, Shapiro 9, 
Boston, MA 
 (0.1 miles away)
617-667-2100
Languages Spoken:
English, Spanish
See accepted insurances

David Mcdermott is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Mcdermott is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Panagiotis Fidias
Internal Medicine
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Panagiotis Fidias
Internal Medicine

Beth Israel Deaconess Medical Center - Hematology/Oncology

330 Brookline Avenue, Shapiro 9, 
Boston, MA 
 (0.1 miles away)
617-667-2100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Panagiotis Fidias is an Internal Medicine provider in Boston, Massachusetts. Dr. Fidias is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Colorectal Cancer.

David J. Einstein
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David J. Einstein
Internal Medicine | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David J. Einstein
Internal Medicine | Oncology

Beth Israel Deaconess Medical Center - Hematology/Oncology

330 Brookline Avenue, Shapiro 9, 
Boston, MA 
 (0.1 miles away)
617-667-2100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Einstein is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Einstein is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Prostatectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bubley's expertise for a condition
ConditionClose
  • Elite
  • Prostate Cancer
    Dr. Bubley is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Distinguished
  • Familial Prostate Cancer
    Dr. Bubley is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Advanced
  • Bladder Cancer
    Dr. Bubley is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Choriocarcinoma
    Dr. Bubley is
    Advanced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Bubley is
    Advanced
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Muscle Invasive Bladder Cancer
    Dr. Bubley is
    Advanced
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Bubley is
    Advanced
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Penile Cancer
    Dr. Bubley is
    Advanced
    . Learn about Penile Cancer.
    See more Penile Cancer experts
View All 12 Advanced Conditions
  • Experienced
  • Bone Marrow Aspiration
    Dr. Bubley is
    Experienced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Clear Cell Sarcoma
    Dr. Bubley is
    Experienced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Pancreatic Cancer
    Dr. Bubley is
    Experienced
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Familial Wilms Tumor 2
    Dr. Bubley is
    Experienced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Lymphofollicular Hyperplasia
    Dr. Bubley is
    Experienced
    . Learn about Lymphofollicular Hyperplasia.
    See more Lymphofollicular Hyperplasia experts
  • Melanoma
    Dr. Bubley is
    Experienced
    . Learn about Melanoma.
    See more Melanoma experts
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved